Janus kinase (JAK) inhibitors, also known as jakinibs, are third-generation oral small
molecules that have expanded the therapeutic options for the management of chronic …

Immune-mediated inflammatory diseases, such as rheumatoid arthritis, psoriatic arthritis,
peripheral and/or axial spondyloarthritis, Crohn's disease, and ulcerative colitis, are …

This is the second European Crohn's and Colitis Organisation [ECCO] evidence-based
consensus on extraintestinal manifestations [EIMs] of inflammatory bowel disease [IBD] and …

Background & Aims Clinicians face difficulty in when and in what order to position biologics
and Janus kinase inhibitors in patients with anti-tumor necrosis factor-alpha (TNF) refractory …

Background Although previous evidence has suggested an increased risk of cardiovascular
disease (CVD) in patients with inflammatory bowel disease (IBD), its association with …

Patients with inflammatory bowel disease (IBD) have an increased risk of developing
venous thromboembolic events, which have a considerable impact on morbidity and …

The European Medicines Agency safety committee has revisited the label and
recommended the use of Janus kinase inhibitors in patients with certain risk factors only if no …

Background and aims Despite the advances in medical therapies, a significant proportion of
patients with inflammatory bowel diseases [IBD] require surgical intervention. This Topical …

Cardiovascular and thromboembolic risks are increasing in the population as a whole and
therefore also in inflammatory bowel disease (IBD) patients. Obesity is a worldwide …

Background In the context of an ageing inflammatory bowel disease (IBD) population,
cardiovascular comorbidities become particularly relevant. Novel small molecule drugs …